GlassScriptPhysician profile
Sandra L Degroat
NPI 1144625799
$4,469.69
in general payments reported to CMS, 2019-2025
18 companies · $1,471 in 2025
The $1,471 reported for 2025 was more than what 88% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,246 · 2022: $633 · 2023: $463 · 2024: $657 · 2025: $1,471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,591.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,004.31 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $849.10 | 2021-2025 | Invega Sustenna, Invega Trinza |
| E.R. Squibb & Sons, L.L.C. | $619.22 | 2024-2025 | Cobenfy |
| Abbvie INC. | $445.48 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $375.30 | 2021-2025 | Austedo, Austedo Xr, Uzedy |
| Alkermes, INC. | $361.68 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Neurocrine Biosciences, INC. | $185.26 | 2021-2023 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $138.01 | 2021-2025 | Abilify Asimtufii, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $123.85 | 2021 | |
| Braeburn INC. | $109.74 | 2025 | Brixadi |
| Indivior INC. | $58.60 | 2021-2022 | |
| Noven Therapeutics, LLC | $56.61 | 2021 | |
| Vanda Pharmaceuticals INC. | $40.90 | 2021-2022 | |
| Corium, LLC | $28.66 | 2022 | |
| Eisai INC. | $28.08 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Pharmaceuticals, INC. | $17.56 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.53 | 2022 | |
| Avanir Pharmaceuticals, INC. | $12.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Degroat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.